These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37278199)

  • 21. Asymptomatic infection after BNT162b2 mRNA COVID-19 vaccination in multiple sclerosis patient.
    Jakimovski D; Weinstock-Guttman B
    Acta Neurol Belg; 2022 Apr; 122(2):565-566. PubMed ID: 34529258
    [No Abstract]   [Full Text] [Related]  

  • 22. General determination of causation between Covid-19 vaccines and possible adverse events.
    Hampton LM; Aggarwal R; Evans SJW; Law B
    Vaccine; 2021 Mar; 39(10):1478-1480. PubMed ID: 33558107
    [No Abstract]   [Full Text] [Related]  

  • 23. Dashboard development for near real-time visualization of COVID-19 vaccine safety surveillance data in the vaccine safety datalink.
    Kenigsberg TA; Hause AM; McNeil MM; Nelson JC; Ann Shoup J; Goddard K; Lou Y; Hanson KE; Glenn SC; Weintraub ES
    Vaccine; 2022 May; 40(22):3064-3071. PubMed ID: 35428497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SIRVA (Shoulder Injury Related to Vaccine Administration) following mRNA COVID-19 Vaccination: Case discussion and literature review.
    Yuen WLP; Loh SYJ; Wang DB
    Vaccine; 2022 Apr; 40(18):2546-2550. PubMed ID: 35339304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 vaccines for children.
    Gerber JS; Offit PA
    Science; 2021 Nov; 374(6570):913. PubMed ID: 34793207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Case report: Acute exacerbation of interstitial pneumonia related to messenger RNA COVID-19 vaccination.
    Amiya S; Fujimoto J; Matsumoto K; Yamamoto M; Yamamoto Y; Yoneda M; Kuge T; Miyake K; Shiroyama T; Hirata H; Takeda Y; Kumanogoh A
    Int J Infect Dis; 2022 Mar; 116():255-257. PubMed ID: 35065256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-allergic nature of vast majority of cutaneous adverse reactions to mRNA COVID-19 vaccines: implications on treatment and re-vaccination.
    Ju T; Lim SYD; Yosipovitch G; Tey HL
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):e861-e862. PubMed ID: 35723902
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety Signal Generation for Sudden Sensorineural Hearing Loss Following Messenger RNA COVID-19 Vaccination: Postmarketing Surveillance Using the French Pharmacovigilance Spontaneous Reporting Database.
    Thai-Van H; Valnet-Rabier MB; Anciaux M; Lambert A; Maurier A; Cottin J; Pietri T; Destère A; Damin-Pernik M; Perrouin F; Bagheri H
    JMIR Public Health Surveill; 2023 Jul; 9():e45263. PubMed ID: 37071555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US.
    Hause AM; Zhang B; Yue X; Marquez P; Myers TR; Parker C; Gee J; Su J; Shimabukuro TT; Shay DK
    JAMA Netw Open; 2022 Jul; 5(7):e2222241. PubMed ID: 35838667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of Guillain-Barré Syndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study.
    Le Vu S; Bertrand M; Botton J; Jabagi MJ; Drouin J; Semenzato L; Weill A; Dray-Spira R; Zureik M
    Neurology; 2023 Nov; 101(21):e2094-e2102. PubMed ID: 37788935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac Complications Associated with COVID-19, MIS-C, and mRNA COVID-19 Vaccination.
    Chin SE; Bhavsar SM; Corson A; Ghersin ZJ; Kim HS
    Pediatr Cardiol; 2022 Mar; 43(3):483-488. PubMed ID: 35258639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and Safety of COVID-19 Vaccinations: An Umbrella Meta-Analysis.
    Jiesisibieke ZL; Liu WY; Yang YP; Chien CW; Tung TH
    Int J Public Health; 2023; 68():1605526. PubMed ID: 37485047
    [No Abstract]   [Full Text] [Related]  

  • 34. Myocarditis After BNT162b2 and mRNA-1273 Vaccination.
    Larson KF; Ammirati E; Adler ED; Cooper LT; Hong KN; Saponara G; Couri D; Cereda A; Procopio A; Cavalotti C; Oliva F; Sanna T; Ciconte VA; Onyango G; Holmes DR; Borgeson DD
    Circulation; 2021 Aug; 144(6):506-508. PubMed ID: 34133884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.
    Ruggiero R; Balzano N; Di Napoli R; Mascolo A; Berrino PM; Rafaniello C; Sportiello L; Rossi F; Capuano A
    Front Immunol; 2022; 13():956825. PubMed ID: 36177033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of myopericarditis following COVID-19 mRNA vaccination in a large integrated health system: A comparison of completeness and timeliness of two methods.
    Sharff KA; Dancoes DM; Longueil JL; Johnson ES; Lewis PF
    Pharmacoepidemiol Drug Saf; 2022 Aug; 31(8):921-925. PubMed ID: 35404496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New-onset Type 1 Diabetes after COVID-19 mRNA Vaccination.
    Yano M; Morioka T; Natsuki Y; Sasaki K; Kakutani Y; Ochi A; Yamazaki Y; Shoji T; Emoto M
    Intern Med; 2022 Apr; 61(8):1197-1200. PubMed ID: 35135929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humoral response to mRNA-based COVID-19 vaccine in patients with de novo and pre-existing immune thrombocytopenia with exacerbation of thrombocytopenia after vaccination.
    Mori A; Onozawa M; Kobayashi M; Tsukamoto S; Ishio T; Yokoyama E; Izumiyama K; Saito M; Muraki H; Morioka M; Teshima T; Kondo T
    Br J Haematol; 2022 Nov; 199(4):627-630. PubMed ID: 36096497
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe.
    Rosenblum HG; Gee J; Liu R; Marquez PL; Zhang B; Strid P; Abara WE; McNeil MM; Myers TR; Hause AM; Su JR; Markowitz LE; Shimabukuro TT; Shay DK
    Lancet Infect Dis; 2022 Jun; 22(6):802-812. PubMed ID: 35271805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reply: Takotsubo Cardiomyopathy After Receiving mRNA COVID-19 Vaccination is Very Rare.
    Gräni C
    Heart Lung Circ; 2022 May; 31(5):e78-e79. PubMed ID: 35144877
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.